SunTrust Robinson Humphrey maintains Buy on Supernus Pharmaceuticals (NASDAQ: SUPN) price target of $61.00.

Analyst Jon Boris says Tokendi XR launch progress and pipeline progress are the focal points.

For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.

Shares of Supernus Pharmaceuticals closed at $41.10 yesterday.